224 related articles for article (PubMed ID: 19435491)
1. The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.
Echouffo-Tcheugui JB; Simmons RK; Williams KM; Barling RS; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
BMC Public Health; 2009 May; 9():136. PubMed ID: 19435491
[TBL] [Abstract][Full Text] [Related]
2. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.
Simmons RK; Borch-Johnsen K; Lauritzen T; Rutten GE; Sandbæk A; van den Donk M; Black JA; Tao L; Wilson EC; Davies MJ; Khunti K; Sharp SJ; Wareham NJ; Griffin SJ
Health Technol Assess; 2016 Aug; 20(64):1-86. PubMed ID: 27583404
[TBL] [Abstract][Full Text] [Related]
3. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial.
Simmons RK; Echouffo-Tcheugui JB; Sharp SJ; Sargeant LA; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
Lancet; 2012 Nov; 380(9855):1741-8. PubMed ID: 23040422
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.
Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ
Trials; 2010 Feb; 11():16. PubMed ID: 20170482
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.
Griffin SJ; Rutten GEHM; Khunti K; Witte DR; Lauritzen T; Sharp SJ; Dalsgaard EM; Davies MJ; Irving GJ; Vos RC; Webb DR; Wareham NJ; Sandbæk A
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):925-937. PubMed ID: 31748169
[TBL] [Abstract][Full Text] [Related]
6. Protocol for the ADDITION-Plus study: a randomised controlled trial of an individually-tailored behaviour change intervention among people with recently diagnosed type 2 diabetes under intensive UK general practice care.
Griffin SJ; Simmons RK; Williams KM; Prevost AT; Hardeman W; Grant J; Whittle F; Boase S; Hobbis I; Brage S; Westgate K; Fanshawe T; Sutton S; Wareham NJ; Kinmonth AL;
BMC Public Health; 2011 Apr; 11():211. PubMed ID: 21463520
[TBL] [Abstract][Full Text] [Related]
7. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
Laxy M; Wilson ECF; Boothby CE; Griffin SJ
Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888
[TBL] [Abstract][Full Text] [Related]
8. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.
Lauritzen T; Griffin S; Borch-Johnsen K; Wareham NJ; Wolffenbuttel BH; Rutten G;
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S6-11. PubMed ID: 11063279
[TBL] [Abstract][Full Text] [Related]
9. Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial.
Van den Donk M; Griffin SJ; Stellato RK; Simmons RK; Sandbæk A; Lauritzen T; Khunti K; Davies MJ; Borch-Johnsen K; Wareham NJ; Rutten GE
Diabetologia; 2013 Aug; 56(11):2367-77. PubMed ID: 23959571
[TBL] [Abstract][Full Text] [Related]
10. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study.
Charles M; Fleischer J; Witte DR; Ejskjaer N; Borch-Johnsen K; Lauritzen T; Sandbaek A
Diabetologia; 2013 Jan; 56(1):101-8. PubMed ID: 23064291
[TBL] [Abstract][Full Text] [Related]
11. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation.
Gray LJ; Khunti K; Williams S; Goldby S; Troughton J; Yates T; Gray A; Davies MJ;
Cardiovasc Diabetol; 2012 May; 11():56. PubMed ID: 22607160
[TBL] [Abstract][Full Text] [Related]
12. Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in 'at risk' individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial.
Simmons RK; Bruun NH; Witte DR; Borch-Johnsen K; Jørgensen ME; Sandbæk A; Lauritzen T
Diabetologia; 2017 Jun; 60(6):1016-1021. PubMed ID: 28280901
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM
BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715
[TBL] [Abstract][Full Text] [Related]
15. Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.
Sortsø C; Komkova A; Sandbæk A; Griffin SJ; Emneus M; Lauritzen T; Simmons RK
Diabetologia; 2018 Jun; 61(6):1306-1314. PubMed ID: 29549417
[TBL] [Abstract][Full Text] [Related]
16. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
Griffin SJ; Borch-Johnsen K; Davies MJ; Khunti K; Rutten GE; Sandbæk A; Sharp SJ; Simmons RK; van den Donk M; Wareham NJ; Lauritzen T
Lancet; 2011 Jul; 378(9786):156-67. PubMed ID: 21705063
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Screening for type 2 diabetes: literature review and economic modelling.
Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
